News

Eidos Therapeutics announced a $64.0 million Series B financing. Proceeds from the financing will be used to advance Eidos' small molecule product candidate, AG10, into Phase 2 clinical…
Read More...

AbbVie announced global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab product. Under the terms of the…
Read More...

Stemline Therapeutics announced that it has initiated its rolling submission of a Biologics License Application (BLA) for SL-401 to the U.S. Food and Drug Administration (FDA). SL-401…
Read More...

PhaseBio Pharmaceuticals announced that it has completed dosing in the first cohort of subjects in its Phase 1 clinical trial of PB2452 (formerly MEDI2452), a reversal agent for the…
Read More...

MyoKardia, Inc. announced that the first patient has been dosed in the company’s Phase 2 MAVERICK-HCM clinical trial. MAVERICK-HCM is the first clinical trial of mavacamten in…
Read More...

Agilent Technologies Inc. and Lasergen, Inc. (Lasergen) announced that they have signed a definitive agreement for Agilent to acquire the remaining shares of Lasergen, an emerging…
Read More...

Ferring Pharmaceuticals and Rebiotix Inc. announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies…
Read More...

Ubiquigent Limited announced that it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel…
Read More...

Cardiva Medical announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE Vascular Closure System.…
Read More...

Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine announced that it has signed a merger agreement with…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist…
Read More...

Aradigm Corporation announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of…
Read More...

Versant Ventures announced that Roche Holdings Inc. has acquired the Inception 5 program, focused on regenerative therapies for multiple sclerosis. Financial terms are not disclosed.…
Read More...

Proteostasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company's triple combination program for the treatment of…
Read More...

Alkermes plc announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily,…
Read More...

AstraZeneca and MedImmune announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational…
Read More...

Compugen Ltd. announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of…
Read More...

Q-State Biosciences announced that the company has entered into a strategic collaboration with Vertex Pharmaceuticals Incorporated to discover drugs using Q-State’s novel Optopatch…
Read More...

Puma Biotechnology and Pint Pharma International have entered into an agreement for Pint Pharma to commercialize NERLYNX (neratinib) in Argentina, Brazil, Chile, Colombia, Mexico and…
Read More...

MRI analysis of patients who received intradiscal injections of human dermal fibroblasts (HDFs) shows significant improvement in disc height after six months. This is the latest…
Read More...